Tag: ISR

Blue Horseshoe Stocks: MDCN Refocus & More

Pervasip Corp. PVSP

To kick off this short week we’d like to take note of PVSP, a super-subpenny stock that has recently awoken from the dead and begun to show some vigorous swings on the chart. PVSP has been bouncing around in a rough channel between .0002 and .0004 for the past couple of weeks.

Every so often we like to watch super-subpennies like this one for the low-risk-high-reward factor; with little room to fall, the rock bottom prices represent a true ground-floor opportunity. Many times in the past have we caught on with a play in this situation and reaped the benefit of rapid and monstrous upswings. We’ll keep a close eye on PVSP for the possible chance to do it again.

Last week the company announced that it had completed deal that will allow it to write approximately $2M off of its existing debt for an up-front sum of just $100K, and a later payment of $25K in October. >>> VIEW PR 

Medican Enterprises, Inc. MDCN

MDCN is a marijuana-related stock that we’ve had on our long term radar for quite some time. Toward the beginning of the year we re-tagged the stock for monitoring and today seems like a good time to focus in more intently on a couple of key points that seem to indicate a possible opportunity ahead.

In addition to a recent property acquisition with potentially exciting implications (PR excerpt below), we’re catching MDCN off of its 52-week low which was just realized on Thursday. Our regular readers are well aware of how fond we are of stocks coming up off of their annual lows. We’ve successfully navigated countless plays in this exact situation, and in many cases have come up with major gains for our efforts.

LAS VEGAS–(BUSINESS WIRE)–Medican Enterprises Inc. (MDCN), a company seeking promising pharmaceutical and other business opportunities in the emerging medical and recreational marijuana sector, announced that it has entered into a purchase agreement to acquire a 7,200 square foot retail and commercial property in Phoenix, Arizona.

The property is currently leased through August 2018 to an Arizona state licensed medical marijuana dispensary. Per the purchase agreement, the lease agreement will be assigned to Medican. >> FULL PR

Extended Watchlist:
CYTR, ISR, AUY, EHTH, SWHC, FRO, IBIO

Blue Horseshoe Stocks: ISR, Bottom Plays & More

IsoRay, Inc. ISR

We first began tracking ISR back in early October as a potential bottom play, and just a few sessions subsequent to our first mention, we would witness a low of 1.22 (10/16).

It took just a couple of weeks for us to ride ISR to a 66% gain as it ran to a high of 2.03 at the end of October. It consolidated down from that level, and for the past month or so the stock has been trading channel between 1.50-1.70.

ISR is catching our attention once again this morning, as we picked up on a new update over the press wire regarding the company’s Cesium-131 low-dose radiation therapy for brain cancer sufferers (Learn More About Cesium-131).

The Barrow Neurological Institute conducted studies with 27 patients with several variations of brain cancer, and the company is reporting that there was no recurrence of the disease on the treated sites in 26 out of the 27 candidates, where other treatments had failed. >> Read PR

We’re going to be interested to see how the stock picks up trading following the holiday week, especially with such an encouraging piece of news out in the premarket. So far, the ISR has gone as high as 2.08 in preliminary trading this morning. We could be looking at a dip-and-scenario once the session commences; to remain interested we’ll want to see support hold at a minimum of 1.89 as that would mark a 50% retrace from the current premarket range.

Potential Bottom Plays

AEterna Zentaris, Inc. AEZS absolutely fell off a cliff back in early November, following FDA denial of a New Drug Application AEZS had submitted. The stock has spent the intervening time bottoming out, and it is now trading at all-time lows. This is exactly the sort of situation that sends us into “vulture-mode”, where we’re on the lookout for any signs of recovery after a stock has been hammered down.

Frontline, Ltd. FRO is a stock that is in the process of coming off of a recent bottom, and is showing signs of life here in today’s premarket, currently trading in the mid-1.30’s.

Extended Watchlist:
JNUG, GRPN, AG, ONNN

Blue Horseshoe Stocks: NVAX, NQ & More

Novavax, Inc. NVAX 

NVAX is the latest Ebola-related stock to catch our eye, and while the initial fear that was driving a lot of these plays has calmed as people realize that the virus doesn’t exactly spread like wildfire, there is much being made of efforts to find a working vaccine and NVAX is attempting to answer that call.

The company announced today that it had presented at the 8th Vaccine and ISV Conference in Philadelphia on Sunday on what was called the first Ebola Vaccine Candidate based on the 2014 Guinea strain that caused the current outbreak in West Africa.

The company said it expects to begin Phase I testing by December, so we’re going to add NVAX to our watchlists for the time being. Additionally, the stock is gapping up to the tune of 10% here in the premarket, and the chart appears to have the possibility of a Golden Cross in the making.

NQ Mobile, Inc. NQ

This is a play we’ve tracked continuously since late this spring. After witnessing a nice move back in July from the low $4-range to the mid-$7’s, the stock had been under general consolidation until it found and bounced off of support about 6 weeks ago. It has made a nice steady recovery from that point on, and is gaining more traction this morning as it gaps up in the premarket on the heels of a PR.

The mobile security has just company submitted the necessary back-filings to once again become fully compliant, and no anomalies or adverse findings were uncovered, which adds another dimension to this play.

We also like the space NQ operates in- with mobile devices permeating every aspect of the current culture, the need for mobile security services such as those provided by NQ only stands to grow in the future.

Side Note:
PTIE, DRRX (Two that are gapping down significantly; we will want to watch for an eventual bounce)

Extended Watchlist:
ISR, AEZS, TSEM, CEMI,